Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Leuk Lymphoma. 2018 May;59(5):1268-1270. doi: 10.1080/10428194.2017.1369067. Epub 2017 Aug 24.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Child
  • Child, Preschool
  • Chromosome Breakpoints*
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / diagnosis
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / genetics*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / pathology
  • Prognosis
  • Promyelocytic Leukemia Protein / genetics*
  • Retinoic Acid Receptor alpha / genetics*
  • Tretinoin / therapeutic use*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Promyelocytic Leukemia Protein
  • RARA protein, human
  • Retinoic Acid Receptor alpha
  • PML protein, human
  • Tretinoin